<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910167</url>
  </required_header>
  <id_info>
    <org_study_id>218.705</org_study_id>
    <nct_id>NCT02910167</nct_id>
  </id_info>
  <brief_title>Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima</brief_title>
  <official_title>Observational Prospective Cohort Study to Evaluate the Incidence of Adverse Events (AE), Risk Factors, and Drug Utilization Patterns Related to Treatment With BUSCAPINA COMPOSITUM N From March to December 2016 in Patients From Metropolitan Lima</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      What AE occur in routine clinical practice, what is the incidence of AE and ADR, how many
      patients present with AE symptoms related to a potential liver injury. What are the drug
      utilization patterns in patients, what are the predisposing factors for the occurrence of
      adverse events and adverse drug reactions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of AEs in routine clinical practice in patients that are in treatment with BUSCAPINA COMPOSITUM N (when it is used according to the label indications)</measure>
    <time_frame>from initial dose until 3 days after the final dose of the drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of patients present with AE symptoms related to a potential liver injury</measure>
    <time_frame>from initial dose until 3 days after the final dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predisposing factors for the occurrence of adverse events and adverse drug reactions in patients who receive BUSCAPINA COMPOSITUM N in Metropolitan Lima Peru</measure>
    <time_frame>from initial dose until 3 days after the final dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AE and ADR in patients that are in treatment with BUSCAPINA COMPOSITUM N when it is used in routine clinical practice according to label indications</measure>
    <time_frame>from initial dose until 3 days after the final dose of the drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug utilization patterns in patients who receive BUSCAPINA COMPOSITUM N in pharmacies, clinics and private doctor's office in Metropolitan Lima Peru</measure>
    <time_frame>from initial dose until 3 days after the final dose of the drug</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Acute Pain</condition>
  <condition>Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>Men with spasmodic syndromes</arm_group_label>
    <description>Men with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Women with spasmodic syndromes</arm_group_label>
    <description>Women with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine n-butylbromide</intervention_name>
    <description>Hyoscine n-butylbromide 10 mg</description>
    <arm_group_label>Men with spasmodic syndromes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Paracetamol 500 mg</description>
    <arm_group_label>Men with spasmodic syndromes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine n-butylbromide</intervention_name>
    <description>Hyoscine n-butylbromide 10 mg</description>
    <arm_group_label>Women with spasmodic syndromes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Paracetamol 500 mg</description>
    <arm_group_label>Women with spasmodic syndromes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Metropolitan Lima
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients 18 years of age and older who have received at least one dose of BUSCAPINA
             COMPOSITUM N according to label indications and who attend to one of the pharmacies,
             clinics, or private doctors office selected for the study.

          2. Patients who agree to adhere to the protocol procedures of this study.

          3. Women who are not pregnant or breast feeding

          4. Persons who sign the informed consent

        Exclusion criteria:

          1. Patients with allergy to BUSCAPINA COMPOSITUM N or any of the compounds in the
             formula.

          2. Patients with mechanical stenosis of the gastrointestinal tract.

          3. Patients with myasthenia gravis.

          4. Patients with megacolon.

          5. Patients breastfeeding at the time of enrollment or who have become pregnant during
             treatment with BUSCAPINA COMPOSITUM N.

          6. Patients with clinical evidence of immunosuppression.

          7. Patients with urinary retention subvesical obstruction (such as prostatic adenoma).

          8. Patients with right-angle glaucoma.

          9. Patients with tachycardia and tachyarrhythmia.

         10. Patients with severe hepatic impairment.

         11. Patients with psychiatric disorders.

         12. Patients with alcohol dependence or drugs.

         13. Patients who discontinue the protocol are not eligible for re-enrollment.

         14. Researchers, company personnel or their relatives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Multiple Locations</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 9, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

